Thermo Fisher Scientific Launches In-Air SARS-CoV-2 Surveillance Solution

WALTHAM, Mass., August 2021 – Thermo Fisher Scientific Inc., the world leader in serving science, announced the launch of the Thermo Scientific AerosolSense Sampler, a new surveillance solution designed to deliver fast and highly reliable insight into the presence of in-air pathogens, including SARS-CoV-2, Flu A/B and RSV.

Individual testing will continue to be a cornerstone in the COVID-19 pandemic response because it enables and informs clinical diagnoses, patient triage and treatment decisions. As society returns to pre-pandemic activities, expanded and complementary monitoring of environments will be key in providing useful insights into virus presence. The AerosolSense Sampler is the next step in providing institutions with highly reliable information to help keep their employees and the public safe.

The AerosolSense Sampler is an in-air pathogen surveillance solution, which collects representative aerosol samples of ambient air and traps in-air pathogens on a collection substrate. The sample can be readily analyzed through subsequent laboratory testing using polymerase chain reaction (PCR) methodology. Confirming the presence of pathogens like SARS-CoV-2 in a space during a known time interval enables decision makers in hospitals and other indoor facilities to take actions to protect their employees and provide the public with confidence.

“Such factors as emerging variants, semi-vaccinated populations and varying levels of compliance with COVID-19 personal safety protocols, continue to pose risks to a society looking to return to life as it was before the pandemic,” said Mark Stevenson, executive vice president and chief operating officer of Thermo Fisher Scientific. “It is important that easy-to-use, highly reliable solutions be available to allow hospitals, nursing homes, schools, businesses and government institutions to identify the presence of in-air pathogens quickly, so safety protocols can be put into action, validated, or strengthened.”

Dr. John Broach, assistant professor of Emergency Medicine at the University of Massachusetts and an early user of the AerosolSense Sampler said, “Monitoring the efficacy of infection control practices is invaluable to protecting health care providers on the frontlines. Combatting COVID-19 is a multi-front battle, and this surveillance solution can be implemented seamlessly within institutions to alert them to the presence of SARS-CoV-2, so that they can take appropriate steps to prevent its spread.”

Thermo Fisher designed the AerosolSense Sampler to capture a wide variety of in-air pathogens and has specifically validated it for SARS-CoV-2, Flu A/B and RSV-B.

For more information, www.thermofisher.com/aps.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $30 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 80,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. For more information, please visit www.thermofisher.com.